MCID: GST049
MIFTS: 49

Gastrointestinal System Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastrointestinal System Cancer

MalaCards integrated aliases for Gastrointestinal System Cancer:

Name: Gastrointestinal System Cancer 12 15
Digestive System Neoplasms 44 72
Gastrointestinal Neoplasms 44 72
Malignant Neoplasm of Gastrointestinal Tract 72
Gastrointestinal Tract Cancer 12
Digestive System Carcinoma 17
Cancer of Digestive System 72
Digestive System Neoplasm 17
Digestive System Cancer 12
Gi Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3119
ICD9CM 35 239.0
NCIt 50 C3052 C4890
SNOMED-CT 68 93811007
ICD10 33 C26.9
UMLS 72 C0012243 C0017185 C0685938 more

Summaries for Gastrointestinal System Cancer

Disease Ontology : 12 An organ system cancer located in gastrointestinal tract that is manifested in organs of the gastrointestinal system.

MalaCards based summary : Gastrointestinal System Cancer, also known as digestive system neoplasms, is related to esophageal cancer and gastric cancer, and has symptoms including signs and symptoms, digestive An important gene associated with Gastrointestinal System Cancer is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are MicroRNAs in cancer and SRF and miRs in Smooth Muscle Differentiation and Proliferation. The drugs Celecoxib and Parecoxib have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and testes.

Related Diseases for Gastrointestinal System Cancer

Diseases related to Gastrointestinal System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 esophageal cancer 33.5 TP53 MIR21 MALAT1 KRAS HOTAIR H19
2 gastric cancer 32.8 TP53 MIR21 MIR145 MIR143 MALAT1 KRAS
3 adenocarcinoma 31.8 TP53 MALAT1 KRAS H19
4 pancreatic cancer 31.7 TP53 MIR21 MIR199A1 MIR143 MIR125A MALAT1
5 gallbladder cancer 31.6 TP53 MALAT1 KRAS HOTAIR H19
6 gastric adenocarcinoma 31.4 TP53 KRAS HOTAIR H19 BANCR AFP
7 oral cancer 31.3 TP53 MIR31 MIR21
8 intrahepatic cholangiocarcinoma 31.3 TP53 KRAS AFP
9 lung cancer susceptibility 3 31.3 TP53 MALAT1 KRAS HOTAIR H19
10 cholangiocarcinoma 31.2 TP53 MIR21 MIR204 MALAT1 KRAS H19
11 pituitary adenoma 31.2 MIR149 MALAT1 HOTAIR H19
12 esophagus squamous cell carcinoma 31.2 HOTAIR BANCR
13 hepatocellular carcinoma 31.2 TP53 MIR338 MIR31 MIR21 MIR145 MIR143
14 small cell cancer of the lung 31.1 TP53 MIR21 MALAT1 HOTAIR
15 retinoblastoma 31.1 TP53 MALAT1 HOTAIR BANCR
16 hyperplastic polyposis syndrome 31.1 TP53 KRAS
17 oral squamous cell carcinoma 31.0 MIR31 MIR21 MIR204 MIR199A1 MIR143 MALAT1
18 gastric cardia adenocarcinoma 31.0 HOTAIR H19
19 pancreatic ductal adenocarcinoma 31.0 MIR31 MIR21 MIR145 MIR143 MALAT1 HOTAIR
20 nasopharyngeal carcinoma 30.9 TP53 MALAT1 HOTAIR H19
21 melanoma 30.9 TP53 MIR338 MIR31 MIR204 MIR149 MALAT1
22 bladder cancer 30.8 TP53 MIR31 MIR21 MIR145 MIR143 MALAT1
23 gastrointestinal system disease 30.8 TP53 KRAS AFP
24 ovarian cancer 30.8 TP53 MIR31 MIR21 MIR145 MIR143 MIR125A
25 lung cancer 30.8 TP53 MIR338 MIR31 MIR21 MIR204 MIR199A1
26 colorectal cancer 30.7 TP53 MIR31 MIR21 MIR145 MIR143 MIR125A
27 prostate cancer 30.6 TP53 SERPINA3 MIR31 MIR21 MIR199A1 MIR149
28 anal canal carcinoma 11.1
29 gastrointestinal neuroendocrine tumor 11.1
30 gastrointestinal carcinoma 11.1
31 pharynx cancer 11.1
32 oral cavity cancer 11.1
33 ovarian epithelial cancer 11.1 MALAT1 HOTAIR H19
34 triple-receptor negative breast cancer 11.0 MALAT1 HOTAIR
35 scrotal carcinoma 11.0 TP53 SERPINA3 AFP
36 thyroid cancer, nonmedullary, 1 11.0 MALAT1 HOTAIR H19 BANCR
37 embryonal sarcoma 11.0 TP53 SERPINA3 MALAT1
38 mature teratoma 11.0 TP53 KRAS AFP
39 osteogenic sarcoma 11.0 TP53 MALAT1 HOTAIR H19 BANCR
40 laryngeal squamous cell carcinoma 11.0 TP53 MIR21 MALAT1 HOTAIR H19
41 ovarian serous carcinoma 11.0 MIR21 MIR145 MIR143 MIR125A
42 prostate disease 11.0 TP53 SERPINA3 MALAT1 H19
43 bile duct adenocarcinoma 11.0 TP53 KRAS AFP
44 esophagus adenocarcinoma 11.0 TP53 MIR21 MIR145 MIR143
45 endometrial adenocarcinoma 11.0 TP53 MIR204 MALAT1 KRAS
46 leukemia, chronic lymphocytic 2 11.0 TP53 MIR145 MIR143 KRAS
47 adamantinoma of long bones 11.0 TP53 MALAT1 KRAS HOTAIR H19
48 myeloma, multiple 11.0 TP53 MALAT1 KRAS HOTAIR H19
49 rare adenocarcinoma of the breast 11.0 TP53 KRAS
50 undifferentiated embryonal sarcoma of the liver 11.0 SERPINA3 MALAT1

Comorbidity relations with Gastrointestinal System Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Cholestasis Deficiency Anemia
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Gastrointestinal System Cancer:



Diseases related to Gastrointestinal System Cancer

Symptoms & Phenotypes for Gastrointestinal System Cancer

UMLS symptoms related to Gastrointestinal System Cancer:


signs and symptoms, digestive

Drugs & Therapeutics for Gastrointestinal System Cancer

Drugs for Gastrointestinal System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 319)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Parecoxib Approved Phase 4 198470-84-7
3
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
4
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
5
Insulin glargine Approved Phase 4 160337-95-1
6
Zinc Approved, Investigational Phase 4 7440-66-6 32051
7
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Enoxaparin Approved Phase 4 9005-49-6 772
11
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
12
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
13
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
14
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
15
Racepinephrine Approved Phase 4 329-65-7 838
16
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
17 Cardiotonic Agents Phase 4
18 Bufanolides Phase 4
19 Cyclooxygenase Inhibitors Phase 4
20 Cyclooxygenase 2 Inhibitors Phase 4
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4
22 Narcotics Phase 4
23 Analgesics, Opioid Phase 4
24 glutamine Phase 4
25 Anti-Arrhythmia Agents Phase 4
26 Neuromuscular Agents Phase 4
27 Neuromuscular Nondepolarizing Agents Phase 4
28 Neuromuscular Blocking Agents Phase 4
29 insulin Phase 4
30 Insulin, Globin Zinc Phase 4
31 Hypoglycemic Agents Phase 4
32 Tocolytic Agents Phase 4
33 Anticonvulsants Phase 4
34 calcium channel blockers Phase 4
35 Anti-Inflammatory Agents Phase 4
36 HIV Protease Inhibitors Phase 4
37
protease inhibitors Phase 4
38 glucocorticoids Phase 4
39 Antineoplastic Agents, Hormonal Phase 4
40 BB 1101 Phase 4
41 Central Nervous System Depressants Phase 4
42 Anticoagulants Phase 4
43 Respiratory System Agents Phase 4
44 Antifungal Agents Phase 4
45 Epinephryl borate Phase 4
46 Sympathomimetics Phase 4
47 Adrenergic Agonists Phase 4
48 Adrenergic alpha-Agonists Phase 4
49 Adrenergic Agents Phase 4
50 Vasoconstrictor Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 437)
# Name Status NCT ID Phase Drugs
1 Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma Unknown status NCT02860429 Phase 4 Cinobufacini injection;chemotherapy
2 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
3 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance, Tramadol PCA and Early Postoperative Enteral Nutrition in Patients After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
4 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
5 A Single-arm, Open-label, Multi-center, Phase Iv, Efficacy And Safety Study Of Sunitinib Malate In The Treatment Of Chinese Patients With Gastrointestinal Stromal Tumor After Disease Progression On Or Intolerance To Imatinib Mesylate Completed NCT00793871 Phase 4 Sunitinib Malate (SU011248)
6 A Phase II Trial Evaluating Irinotecan and Capecitabine in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
7 Comparing With Traditional Nitrogen Calorie Parenteral Nutrition Support, the Impact of Low Calorie and Low Nitrogen Intake on the Clinical Outcome of Gastrointestinal Postoperative Patients, Multicentre Post-Marketing Clinical Study Completed NCT00247338 Phase 4 low calorie, low nitrogen parenteral nutrition for patient with NRS score 3
8 The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies - A Randomized, Placebo-controlled Pilot Study Completed NCT01552291 Phase 4 Placebo
9 Assessment the Effect of Medium-Calorie TPN on Patients With Gastrointestinal Cancer Undergoing Surgery Completed NCT01700062 Phase 4
10 Muscle Relaxation During Open Upper Abdominal Surgery - Can the Surgical Conditions be Optimized? Completed NCT02140593 Phase 4 Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).;Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.
11 Glargine Insulin Versus Continous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) Completed NCT02216799 Phase 4 Glargine Insulin;Regular insulin
12 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
13 Comparison of Thromboembolic Events in Patients Undergoing Gastrointestinal Cancer Surgery and Thromboprophylactic Treatment With Two Enoxaparin Formulations (ENOXA® vs Lovenox®) Recruiting NCT02444572 Phase 4 Enoxaparin 4000 IU
14 Efficacy of Rapamycin (Sirolimus) in the Treatment of Blue Rubber Bleb Nevus Syndrome, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
15 A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial Recruiting NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
16 Randomized Controlled Trial of Hemostatic Powder Versus Optimal Clinical Management for the Treatment of Upper Gastrointestinal Bleeding From Tumor Lesions Not yet recruiting NCT02820077 Phase 4
17 Clinical Trial on Ganoderma Spore Lipids Combined With Chemo in Patients With G.I. Cancers Unknown status NCT02785523 Phase 3 Ganoderma Spore Lipids;Placebo;Chemotherapy
18 Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization for the Treatment of Colorectal Liver Metastases (SIM Trial) Unknown status NCT02208804 Phase 2, Phase 3
19 A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
20 Endoscopic Ultrasonography Guided Fine Needle Biopsy (EUS-FNB) vs. Single-incision Needle-knife (SINK) Biopsy for Diagnosis of Upper Gastrointestinal Subepithelial Lesions Unknown status NCT02866045 Phase 3
21 Peri-operative Usage of Enteric Immune-nutrition Formula (ANOM®) Versus Standard Formula for Patients Received Major Upper Gastrointestinal Surgery Unknown status NCT01351883 Phase 3
22 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
23 A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone in the Second Line Treatment of ErbB2 Amplified Advanced Gastric Cancer Completed NCT00486954 Phase 3 Lapatinib;Paclitaxel
24 Prospective Study on the Value of Subcutaneous Drains in Gastrointestinal Surgery Completed NCT00826410 Phase 3
25 Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP) Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
26 A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Completed NCT01996306 Phase 3 CPT-11 (Irinotecan);5-FU Bolus;5-FU Infusion;l-LV (dl-LV);CPT-11 (Irinotecan);Capecitabine
27 A Clinical Randomized Control Trial of Combination TACE With and Without Low-molecular-weight Heparin in Hepatocellular Carcinoma Completed NCT00827554 Phase 2, Phase 3 LMWH
28 Randomized Trial Comparing Drainage Versus no Drainage Following Rectal Excision With Low Anastomosis for Rectal Cancer Completed NCT01269567 Phase 3
29 A Prospective Random Assignment Trial to Study Operative Debulking and Systemic Chemotherapy With or Without Intra-and Peri-Operative Intraperitoneal Chemotherapy for Subjects With Peritoneal Carcinomatosis From Low Grade Gastrointestinal Adenocarcinoma Completed NCT00052962 Phase 3
30 Immunonutrition to Improve Quality of Life of Upper Gastrointestinal Cancer Patients Undergoing Oncological Treatment Completed NCT01423799 Phase 3
31 A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm Completed NCT02112656 Phase 3 ThermoDox;Dummy infusion
32 Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer: A Multicenter Randomized Clinical Trial Completed NCT02664974 Phase 3
33 Monosialotetrahexosylganglioside Sodium Injection for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Completed NCT02486198 Phase 3 placebo;GM;oxaliplatin-based chemotherapy
34 A Randomized Clinical Trial of Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients Completed NCT00513357 Phase 3 Melatonin;Placebo
35 A Multinational, Randomized, Phase III Study of FOLFIRI With/Without Bevacizumab Versus Irinotecan With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Recruiting NCT03303495 Phase 3 CPT-11;5-FU Bolus;5-FU Infusion;l-LV (dl-LV)
36 A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Recruiting NCT03464305 Phase 3 acetylsalicylic acid;Placebo
37 Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
38 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
39 A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC). Active, not recruiting NCT02753127 Phase 3 Napabucasin;Fluorouracil;Leucovorin;Irinotecan;Bevacizumab
40 A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib Active, not recruiting NCT00680901 Phase 3 Lapatinib;Placebo;Capecitabine;Oxaliplatin
41 A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma Active, not recruiting NCT01964430 Phase 3 nab-Paclitaxel 125 mg/m2;gemcitabine 1000 mg/m2;gemcitabine 1000 mg/m2
42 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
43 An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer Active, not recruiting NCT02322593 Phase 3 TAS-118 plus Oxaliplatin;S-1 plus Cisplatin
44 A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer Not yet recruiting NCT03889626 Phase 3 Apatinib;Capecitabine
45 An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) Terminated NCT01009593 Phase 3 ABT-869;Sorafenib
46 A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery Terminated NCT00254436 Phase 3 Procrit (epoetin alfa)
47 Effect of 3 Day Pre-operative Immunonutrition Regimen on Clinical Outcome in Well-nourished Patients With Gastrointestinal Cancer Undergoing Surgery , a Randomised Double-blind Controlled Trial Terminated NCT01023412 Phase 3
48 A Prospective, Randomised, Multicenter Phase II/III Clinical Trial to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT Versus Placebo Terminated NCT00332280 Phase 2, Phase 3 AMT2003
49 A Randomized, Double Blind, Two Period, Placebo-Controlled Crossover Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients Terminated NCT00516269 Phase 3 Methylphenidate;Placebo
50 Does Radiation Therapy Adversely Affect the Immune System, and Can Acupuncture Ameliorate the Effect? A Pilot Study Withdrawn NCT01422928 Phase 3

Search NIH Clinical Center for Gastrointestinal System Cancer

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Imatinib mesylate

Cochrane evidence based reviews: digestive system neoplasms

Genetic Tests for Gastrointestinal System Cancer

Anatomical Context for Gastrointestinal System Cancer

MalaCards organs/tissues related to Gastrointestinal System Cancer:

41
Liver, Colon, Testes, Lung, Breast, Lymph Node, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Gastrointestinal System Cancer:

19
Gastrointestinal Tract

Publications for Gastrointestinal System Cancer

Articles related to Gastrointestinal System Cancer:

(show top 50) (show all 415)
# Title Authors PMID Year
1
"-Omas" presenting as "-itis": acute inflammatory presentations of common gastrointestinal neoplasms. 38
30719599 2019
2
Generation of magnifying endoscopic images of gastric neoplasms based on an all-in-focus algorithm. 38
31334881 2019
3
Learning Curve for Endoscopic Submucosal Dissection With an Untutored, Prevalence-Based Approach in the United States. 38
31220645 2019
4
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. 38
31239549 2019
5
Efficacy and safety of steroid in the prevention of esophageal stricture after endoscopic submucosal dissection: A network meta-analysis. 38
30566746 2019
6
Short-term outcomes of traction-assisted versus conventional endoscopic submucosal dissection for superficial gastrointestinal neoplasms: a systematic review and meta-analysis of randomized controlled studies. 38
31164139 2019
7
Efficacy of scissor-type knives for endoscopic mucosal dissection of superficial gastrointestinal neoplasms. 38
31120558 2019
8
Correlation of molecular and morphological features of appendiceal epithelial neoplasms. 38
31111538 2019
9
Management of adverse events related to endoscopic resection of upper gastrointestinal neoplasms: Review of the literature and recommendations from experts. 38
30994225 2019
10
Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis. 38
30763436 2019
11
Predicting outcomes in colorectal endoscopic submucosal dissection: a United States experience. 38
30725255 2019
12
Identification of the critical viscoelastic factor in the performance of submucosal injection materials. 38
30423779 2019
13
Jejunal GIST: Hunting down an unusual cause of gastrointestinal bleed using double balloon enteroscopy. A case report. 38
31277041 2019
14
Pitfalls in the Interpretation of Publications about Endoscopic Submucosal Dissection of Early Gastric Cancer with Undifferentiated-Type Histology. 38
30650945 2019
15
A Rare Case of a Ruptured Metastatic Hepatic Lesion from a Jejunal Gastrointestinal Stromal Tumor (GIST) Treated by Arterial Embolization. 38
30542049 2018
16
Organoid models of gastrointestinal Neoplasms: Origin, current status and future applications in personalized medicine. 38
30591933 2018
17
Ambient air pollution in gastrointestinal endoscopy unit; rationale and design of a prospective study. 38
30544484 2018
18
Switching from endoscopic submucosal dissection to salvage piecemeal knife-assisted snare resection to remove a lesion: A preoperative risk score from the beginning. 38
30221971 2018
19
Modular laser-based endoluminal ablation of the gastrointestinal tract: in vivo dose-effect evaluation and predictive numerical model. 38
30456508 2018
20
Clinical Presentation of Gastrointestinal Stromal Tumors. 38
30498699 2018
21
Prognostic factors for death after surgery for small intestinal neuroendocrine tumours. 38
30263986 2018
22
Characteristic findings of high-grade cervical intraepithelial neoplasia or more on magnifying endoscopy with narrow band imaging. 38
29446041 2018
23
Feasibility of robotic resection of gastrointestinal stromal tumors along the entire gastrointestinal tract. 38
30019164 2018
24
[Endoscopic techniques for early stage cancer of the upper and lower gastrointestinal tract : Possibilities and limitations]. 38
29188354 2018
25
A novel gel immersion technique using a bipolar needle-knife in endoscopic submucosal dissection for superficial gastrointestinal neoplasms. 38
29507476 2018
26
The effect of chemotherapy on nutritional status and weakness in geriatric gastrointestinal system cancer patients. 38
29429533 2018
27
Development of a new ex vivo model for evaluation of endoscopic submucosal injection materials performance. 38
29329031 2018
28
Multiple neuroendocrine tumor of the small bowel: a case report and a review of literature. 38
30590945 2018
29
Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma. 38
29662529 2018
30
Gigantic GIST: A Case of the Largest Gastrointestinal Stromal Tumor Found to Date. 38
30363960 2018
31
Gastrointestinal malignant neoplasms disguised as pneumatosis cystoids intestinalis: A case report and literature review. 38
29390561 2017
32
Comparison of endoscopic ultrasonography and magnifying endoscopy for assessment of the invasion depth of shallow gastrointestinal neoplasms: a systematic review and meta-analysis. 38
28547665 2017
33
[Current status of hereditary gastrointestinal neoplasms]. 38
29178089 2017
34
Comparison of sedation between the endoscopy room and operation room during endoscopic submucosal dissection for neoplasms in the upper gastrointestinal tract. 38
29179691 2017
35
The effect of intraoperative hypothermia upon blood transfusion needs and length of stay among gastrointestinal system cancer surgery. 38
28417506 2017
36
[Duodenal leiomyoma - a rare case report]. 38
28876117 2017
37
Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. 38
28674119 2017
38
SATB1 overexpression correlates with gastrointestinal neoplasms invasion and metastasis: a meta-analysis for Chinese population. 38
28636989 2017
39
Biomedical optical spectroscopy for the early diagnosis of gastrointestinal neoplasms. 38
28671054 2017
40
Evolving role of the endoscopist in management of gastrointestinal neuroendocrine tumors. 38
28785139 2017
41
Evaluation of endoscopic submucosal dissection using a new endosurgical knife DN-D2718B: a first clinical feasibility study. 38
28691052 2017
42
Small bowel malignancy in patients undergoing capsule endoscopy at a tertiary care academic center: Case series and review of the literature. 38
28573179 2017
43
CA 19-9 as a Marker of Survival and a Predictor of Metastization in Cholangiocarcinoma. 38
28848795 2017
44
Effects of argon plasma coagulation on human stomach tissue: An ex vivo study. 38
27862273 2017
45
An Epithelioid Gastrointestinal Stromal Tumor of the Stomach With Strong Expression of Keratin: Clinicopathologic Correlation and Follow-up Post-Imatinib Therapy. 38
28362703 2017
46
Colonic endoscopic full-thickness resection (EFTR) with the over-the-scope device (FTRD): a short case series. 38
28112966 2017
47
High-Grade Mixed Adenoneuroendocrine Carcinoma in the Cecum: A Case Report. 38
28289663 2017
48
Gastrointestinal stromal tumors in kidney transplant recipients: Report of two cases and literature review. 38
27461055 2017
49
Hyperthermic intraperitoneal chemotherapy plus high-frequency diathermic therapy followed by intravenous chemotherapy versus intravenous chemotherapy alone for postoperative adjuvant treatment of gastrointestinal cancer: a comparative research study. 38
28039716 2016
50
A rare case with synchronous gastric gastrointestinal stromal tumor, pancreatic neuroendocrine tumor, and uterine leiomyoma. 38
27846844 2016

Variations for Gastrointestinal System Cancer

Expression for Gastrointestinal System Cancer

Search GEO for disease gene expression data for Gastrointestinal System Cancer.

Pathways for Gastrointestinal System Cancer

Pathways related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.77 TP53 MIR31 MIR21 MIR199A1 MIR17 MIR145
2 10.27 MIR199A1 MIR145
3 10.03 TP53 HOTAIR

GO Terms for Gastrointestinal System Cancer

Cellular components related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 SERPINA3 MIR338 MIR31 MIR21 MIR204 MIR199A1

Biological processes related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cellular response to hypoxia GO:0071456 9.73 TP53 MIR17 MALAT1
2 negative regulation of angiogenesis GO:0016525 9.56 MIR21 MIR145 MIR143 MIR125A
3 regulation of smooth muscle contraction GO:0006940 9.55 MIR145 MIR143
4 negative regulation of cardiac muscle hypertrophy GO:0010614 9.54 MIR21 MIR145
5 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.54 MIR21 MIR199A1 MIR145
6 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.52 MIR21 MIR17
7 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.51 MIR199A1 MIR17
8 positive regulation of metalloendopeptidase activity GO:1904685 9.49 MIR21 MIR17
9 angiotensin-activated signaling pathway GO:0038166 9.48 MIR145 MIR143
10 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.46 MIR21 MIR17
11 aorta smooth muscle tissue morphogenesis GO:0060414 9.43 MIR145 MIR143
12 regulation of phenotypic switching GO:1900239 9.4 MIR145 MIR143
13 gene silencing by miRNA GO:0035195 9.4 MIR338 MIR31 MIR21 MIR204 MIR199A1 MIR196A1
14 miRNA mediated inhibition of translation GO:0035278 9.35 MIR31 MIR21 MIR204 MIR17 MIR145
15 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.32 MIR17 MIR143
16 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.16 MIR145 MIR143

Molecular functions related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.32 MIR31 MIR21 MIR204 MIR199A1 MIR196A1 MIR17

Sources for Gastrointestinal System Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....